A Phase 2, Randomized, Open-Label Study Of Single Agent CI-1033 In Patients With Advanced Non-Small Cell Lung Cancer
Status:
Completed
Trial end date:
2005-11-01
Target enrollment:
Participant gender:
Summary
The purpose of study to determine the activity of CI 1033 against tumors in patients with
advanced or metastatic NSCLC who have failed prior platinum-based combination chemotherapy.
Another objective is to determine the safety of CI 1033.